Acetic Acid Derivatives of 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxide as a Novel Class of Potent Aldose Reductase Inhibitors

被引:53
作者
Chen, Xin [1 ]
Zhu, Changjin [1 ]
Guo, Fan [1 ]
Qiu, Xiaowei [1 ]
Yang, Yanchun [1 ]
Zhang, Shuzhen [1 ]
He, Minlan [1 ]
Parveen, Shagufta [1 ]
Jing, Chaojun [1 ]
Li, Yan [2 ]
Ma, Bing [1 ]
机构
[1] Beijing Inst Technol, Dept Appl Chem, Sch Chem Engn & Environm, Beijing 100081, Peoples R China
[2] Beijing Inst Technol, Sch Life Sci & Biotechnol, Beijing 100081, Peoples R China
基金
北京市自然科学基金;
关键词
POSITIVE ALLOSTERIC MODULATORS; DIABETIC COMPLICATIONS; ALDEHYDE REDUCTASE; HIGHLY POTENT; CONGENERS; RAT; ACCUMULATION; RECEPTORS; TOLRESTAT; DESIGN;
D O I
10.1021/jm100962a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of novel benzothiadiazine 1,1-dioxide derivatives were synthesized and tested for their inhibitory activity against aldose reductase. Of these derivatives, 17 compounds, having a substituted N2-benzyl group and a N4-acetic acid group on the benzothiadiazine, were found to be potent and selective aldose reductase inhibitors in vitro with IC50 values ranging from 0.032 to 0.975 mu M. 9m proved to be the most active in vitro. The eight top-scoring compounds coming from the in vitro test for ALR2 inhibition activity were then tested in vivo, whereby three derivatives, 9i, 9j, and 9m, demonstrated a significantly preventive effect on sorbitol accumulation in the sciatic nerve in the 5-day streptozotocin-induced diabetic rats in vivo. Structure activity relationship and molecular docking studies highlighted the importance of substitution features of N4-acetic acid group and halogen-substituted N2-benzyl group in the benzothiadiazine scaffold and indicated that substitution with hallogen at C-7 had a remarkably strong effect on ALR2 inhibition potency.
引用
收藏
页码:8330 / 8344
页数:15
相关论文
共 55 条
[1]   Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century [J].
Alexiou, Polyxeni ;
Pegklidou, Kyriaki ;
Chatzopoulou, Maria ;
Nicolaou, Ioannis ;
Demopoulos, Vassilis J. .
CURRENT MEDICINAL CHEMISTRY, 2009, 16 (06) :734-752
[2]   CHARACTERIZATION OF A NOVEL ALDOSE REDUCTASE INHIBITOR, FR74366, AND ITS EFFECTS ON DIABETIC CATARACT AND NEUROPATHY IN THE RAT [J].
AO, S ;
SHINGU, Y ;
KIKUCHI, C ;
TAKANO, Y ;
NOMURA, K ;
FUJIWARA, T ;
OHKUBO, Y ;
NOTSU, Y ;
YAMAGUCHI, I .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (01) :77-87
[3]   Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients [J].
Asano, T ;
Saito, Y ;
Kawakami, M ;
Yamada, N .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2002, 16 (02) :133-138
[4]   The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity [J].
Barski, OA ;
Gabbay, KH ;
Bohren, KM .
BIOCHEMISTRY, 1996, 35 (45) :14276-14280
[5]  
Bergmeyer H.U., 1974, Methods of Enzymatic Analysis, V3rd, P1323
[6]  
BOHREN KM, 1992, J BIOL CHEM, V267, P20965
[7]   Synthesis of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide derivatives as potential allosteric modulators of AMPA/kainate receptors [J].
Braghiroli, D ;
Puia, G ;
Cannazza, G ;
Tait, A ;
Parenti, C ;
Losi, G ;
Baraldi, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2355-2357
[8]   BIOLOGICAL AND BIOCHEMICAL ANTI-HIV ACTIVITY OF THE BENZOTHIADIAZINE CLASS OF NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
PYLE, CA ;
WHITE, EL ;
BOWDEN, BJ ;
MCMAHON, JB ;
BOYD, MR ;
BADER, JP ;
NICKELL, DG ;
BARTH, H ;
ANTONUCCI, TK .
ANTIVIRAL RESEARCH, 1994, 25 (01) :43-56
[9]   A SUPERFAMILY OF NADPH-DEPENDENT REDUCTASES IN EUKARYOTES AND PROKARYOTES [J].
CARPER, DA ;
WISTOW, G ;
NISHIMURA, C ;
GRAHAM, C ;
WATANABE, K ;
FUJII, Y ;
HAYASHI, H ;
HAYAISHI, O .
EXPERIMENTAL EYE RESEARCH, 1989, 49 (03) :377-388
[10]   Genetic analysis of aldose reductase in diabetic complications [J].
Chung, SSM ;
Chung, SK .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (15) :1375-1387